This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): Atazanavir sulfate, ATV, BMS-232632
Description: Reyataz (atazanavir sulfate) is an azapeptide inhibitor of HIV–1 protease. The inhibition of viral protease prevents the cleavage of the gag-pol polyprotein. This results in the production of immature, noninfectious virus.
Deal Structure: Bristol-Myers developed atazanavir under a worldwide license from Novartis, for which a royalty is paid based on a percentage of net sales. Bristol-Myers is entitled to promote Reyataz for use in combination with Norvir (ritonavir) under a non-exclusive license agreement with Abbott Laboratories, as amended, for which a royalty is paid based on a percentage of net sales.
In November 2011, Bristol-Myers Squibb announced a technology transfer agreement with the Brazilian Ministry of Health to expand access to Reyataz in Brazil. The agreement transfers the manufacture and distribution of atazanavir sulfate 200 mg and 300 mg capsules in Brazil from Bristol-Myers Squibb to Farmanguinhos, a technical-scientific unit of Fundao Oswaldo Cruz (Fiocruz) and the largest official pharmaceutical laboratory of the Brazilian Ministry of Health, and to a yet to be named local manufacturer of active pharmaceutical ingredients (API).
Partners: Novartis AG AbbVie Inc.
Additional information available to subscribers only: